This, along with another similar study (Paez-Ribes et al,2009), raised the possibility that VEGF pathway inhibitionmay change the natural history of tumor progression after antiangiogenic therapy and includepotential metastasis-promoting effects. Here, VEGFA is linked to neoplasm.